Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic GVHD
NCT04294641Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in chronic graft-versus-host disease (cGVHD), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate at 6 months. Started May 2021; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04294641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294641.